Study of Paclitaxel-albumin Plus Anti-angiogenesis in Patients with Advanced Transitional Cell Carcinoma of the Urothelium
Wang Xuan;Si Lu;Mao Li-li;Chi Zhi-hong;Sheng Xi-nan;Cui Chuan-liang;Kong Yan;Tang Bi-xia;Yan Xie-qiao;Guo Jun;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute;
Objective The treatment of patients with recurrent advanced transitional cell carcinoma of the urotheliumthat progressed after prior platinum-based chemotherapy remains an unmet clinical need. This study assessed the antitumor activity of paclitaxel-albuminplus anti-angiogenesisas no-first-line treatment in patients with advanced transitional cell carcinoma of the urothelium, retrospectively. Methods 23 patients with advanced transitional cell carcinoma of the urothelium were enrolled this single arm study. Patients received paclitaxel-albuminplus anti-angiogenesis(Bevacizumabor Endostatin) treatment. Results The mean treatment of 23 patients were 3.0 cycles. 2 patients had partial response(8.7%), 9 patients had stable disease(39.1%). Overall response rate(ORR) was 21.7%. Median progression-free survival was 12.0 weeks.Hematologic leukopenia was the most common toxicity(52.2%). Until last follow up(median follow-up time 7.0 months), 22 patients dead. Median overall survival was 7.0months. Conclusion Paclitaxel-albuminplus anti-angiogenesisis safe and active as no-first-line treatment in patients with advanced transitional cell carcinoma of the urothelium. Additional evaluation is still warranted.
【CateGory Index】： R737.1